Expression and localization of tissue factor pathway inhibitor-2 in normal and atherosclerotic human vessels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 2, 2002, Pages 218-224

  Crawley, James T B ^a   Goulding, David A ^a   Ferreira, Valérie ^a   Severs, Nicholas J ^a   Lupu, Florea ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Atherosclerosis; Matrix metalloproteinases; Plasmin; Tissue factor; Tissue factor pathway inhibitor 2

Indexed keywords

PLACENTA PROTEIN 5; SERINE PROTEINASE INHIBITOR;

ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEUKEMIA CELL LINE; MONOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER;

BLOTTING, WESTERN; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; FACTOR VIIA; GLYCOPROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MACROPHAGES; MICROSCOPY, ELECTRON; MUSCLE, SMOOTH, VASCULAR; PLASMINOGEN; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 0036162125     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/hq0102.101842     Document Type: Article

References (30)

1. Isolation and characterization of the placental protein pp5
2. Evidence that a second human tissue factor pathway inhibitor (TFPI-2) and human placental protein 5 are equivalent
3. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor
4. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: Heparin accelerates the activity of TFPI-2/MSPI toward plasmin
5. cDNA cloning and mRNA expression of a serine proteinase inhibitor secreted by cancer cells: Identification as placental protein 5 and tissue factor pathway inhibitor-2
6. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2
7. Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2
8. Vascular endothelial genes that are responsive to tumor necrosis factor-α in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes
9. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor
10. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis
11. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI
12. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor
13. Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells
14. Tissue factor pathway inhibitor-2 is a novel mitogen for vascular smooth muscle cells
15. Atherosclerosis: An inflammatory disease
16. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels
17. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis
18. Tumor cell adhesion and migration supported by interaction of a recepto-protease complex with its inhibitor
19. Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies
20. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
21. In situ analysis of tissue factor-dependent thrombin generation in human atherosclerotic vessels
22. Inhibition of cell surface receptor-bound plasmin by α2-antiplasmin and α2-macroglobulin
23. The plasminogen (fibrinolytic) system
24. Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocytic cells
25. Plasminogen activator expression in human atherosclerotic lesions
26. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
27. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall
28. Cellular regulation of fibrinolysis
29. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases
30. Immunofluorometric demonstration and quantification of placental protein 5 in the absence of pregnancy